Telehealth coaching for shared decision-making in lung cancer screening
TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary carE (TELESCOPE)
This study tests if a remote coaching program can help people make better decisions about lung cancer screening compared to regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 594 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rutgers, The State University of New Jersey Academic / other |
| Locations | 2 sites (New Brunswick, New Jersey and 1 other locations) |
| Trial ID | NCT05491213 on ClinicalTrials.gov |
What this trial studies
This intervention compares the effectiveness of the TELESCOPE program, which provides remote decision coaching, against enhanced usual care for improving shared decision-making in lung cancer screening. The study aims to increase knowledge about lung cancer screening benefits and harms, reduce decisional conflict, and enhance screening uptake and adherence. It also evaluates the potential for implementing navigator-led decision coaching in clinical settings. The study will involve a cluster randomized trial with a mixed methods approach to assess both quantitative and qualitative outcomes.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 50 to 77 who are current or former smokers with a significant smoking history and are scheduled for a non-acute care visit.
Not a fit: Patients who do not meet the age or smoking history criteria, or those who are not scheduled for a non-acute care visit, may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could lead to improved lung cancer screening rates and better-informed patients, ultimately enhancing early detection and treatment outcomes.
How similar studies have performed: Other studies have shown promise in using shared decision-making approaches for cancer screening, suggesting that this intervention could be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Inclusion Criteria Cluster Randomized Trial Eligibility of patients for the cluster randomized trial will follow United States Preventive Services Task Force criteria for lung cancer screening. Specifically, patients must: * Be 50 to 77 years of age * Be a current or former smoker having quit within the past 15 years * Have at least a 20 pack-year smoking history * Be scheduled for a non-acute care visit at one of the study sites. Interviews (N=50) Participants completing the semi-structured interviews will be: * A practicing primary care clinician or a clinic director (n=20), nursing director, or clinic practice administrator (n=20) at one of the participating sites or a TELESCOPE study patient navigator (n=7) and nurse navigator (n = 3) * Age 18 or older * Fluent in English Online surveys (N=130) Providers completing online PRISM construct surveys will be: * A practicing primary care provider at one of the participating sites or a TELESCOPE study navigator * Age 18 or older * Fluent in English Exclusion Criteria: \- Cluster Randomized Trial Excluded will be patients who: * Do not speak English * Have a history lung cancer * Were screened for lung cancer within the past 12 months * Have health conditions that make them poor candidates for curative treatment as determined by the primary care provider * Are unable to provide informed consent Interviews (N=50) Providers/administrators will be excluded if they: * Are unable to provide informed consent Online surveys (N=130) * Are unable to provide informed consent * Women who are pregnant. English proficiency is required for the completion of surveys, and the intervention will be conducted in English.
Where this trial is running
New Brunswick, New Jersey and 1 other locations
- Rutgers Cancer Institute — New Brunswick, New Jersey, United States (Recruiting)
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (Active_not_recruiting)
Study contacts
- Principal investigator: Anita Y Kinney, PhD, RN — Rutgers Cancer Institute
- Study coordinator: Julie E Chapman-Greene, PhD, MPH
- Email: chapmaje@cinj.rutgers.edu
- Phone: 732-865-3375
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.